vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Upstart Holdings, Inc. (UPST). Click either name above to swap in a different company.
Upstart Holdings, Inc. is the larger business by last-quarter revenue ($296.1M vs $284.0M, roughly 1.0× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 6.3%, a 90.0% gap on every dollar of revenue. On growth, Upstart Holdings, Inc. posted the faster year-over-year revenue change (35.2% vs 9.4%). Over the past eight quarters, Upstart Holdings, Inc.'s revenue compounded faster (52.2% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Upstart is an AI lending platform that partners with banks and credit unions to provide consumer loans using non-traditional variables, such as education and employment, to predict creditworthiness.
ACAD vs UPST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $296.1M |
| Net Profit | $273.6M | $18.6M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 6.4% |
| Net Margin | 96.3% | 6.3% |
| Revenue YoY | 9.4% | 35.2% |
| Net Profit YoY | 90.3% | 776.4% |
| EPS (diluted) | $1.61 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $296.1M | ||
| Q3 25 | $278.6M | $277.1M | ||
| Q2 25 | $264.6M | $257.3M | ||
| Q1 25 | $244.3M | $213.4M | ||
| Q4 24 | $259.6M | $219.0M | ||
| Q3 24 | $250.4M | $162.1M | ||
| Q2 24 | $242.0M | $127.6M | ||
| Q1 24 | $205.8M | $127.8M |
| Q4 25 | $273.6M | $18.6M | ||
| Q3 25 | $71.8M | $31.8M | ||
| Q2 25 | $26.7M | $5.6M | ||
| Q1 25 | $19.0M | $-2.4M | ||
| Q4 24 | $143.7M | $-2.8M | ||
| Q3 24 | $32.8M | $-6.8M | ||
| Q2 24 | $33.4M | $-54.5M | ||
| Q1 24 | $16.6M | $-64.6M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 6.4% | ||
| Q3 25 | 12.8% | 8.5% | ||
| Q2 25 | 12.2% | 1.8% | ||
| Q1 25 | 7.9% | -2.1% | ||
| Q4 24 | 59.1% | -2.2% | ||
| Q3 24 | 12.6% | -27.8% | ||
| Q2 24 | 12.6% | -43.5% | ||
| Q1 24 | 7.4% | -52.8% |
| Q4 25 | 96.3% | 6.3% | ||
| Q3 25 | 25.8% | 11.5% | ||
| Q2 25 | 10.1% | 2.2% | ||
| Q1 25 | 7.8% | -1.1% | ||
| Q4 24 | 55.4% | -1.3% | ||
| Q3 24 | 13.1% | -4.2% | ||
| Q2 24 | 13.8% | -42.7% | ||
| Q1 24 | 8.0% | -50.5% |
| Q4 25 | $1.61 | $0.20 | ||
| Q3 25 | $0.42 | $0.23 | ||
| Q2 25 | $0.16 | $0.05 | ||
| Q1 25 | $0.11 | $-0.03 | ||
| Q4 24 | $0.86 | $-0.01 | ||
| Q3 24 | $0.20 | $-0.07 | ||
| Q2 24 | $0.20 | $-0.62 | ||
| Q1 24 | $0.10 | $-0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $652.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $798.8M |
| Total Assets | $1.6B | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $652.4M | ||
| Q3 25 | $258.0M | $489.8M | ||
| Q2 25 | $253.6M | $395.9M | ||
| Q1 25 | $217.7M | $599.8M | ||
| Q4 24 | $319.6M | $788.4M | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | $798.8M | ||
| Q3 25 | $917.3M | $743.7M | ||
| Q2 25 | $822.4M | $722.0M | ||
| Q1 25 | $765.2M | $676.6M | ||
| Q4 24 | $732.8M | $633.2M | ||
| Q3 24 | $577.2M | $595.5M | ||
| Q2 24 | $516.7M | $594.7M | ||
| Q1 24 | $464.0M | $612.8M |
| Q4 25 | $1.6B | $3.0B | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.2B | $2.4B | ||
| Q3 24 | $976.9M | $1.8B | ||
| Q2 24 | $914.1M | $1.8B | ||
| Q1 24 | $855.1M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $108.6M |
| Free Cash FlowOCF − Capex | — | $108.4M |
| FCF MarginFCF / Revenue | — | 36.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | -0.18× | 5.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $108.6M | ||
| Q3 25 | $74.3M | $-122.6M | ||
| Q2 25 | $64.0M | $-120.2M | ||
| Q1 25 | $20.3M | $-13.5M | ||
| Q4 24 | $40.4M | $-110.9M | ||
| Q3 24 | $63.2M | $179.3M | ||
| Q2 24 | $25.0M | $65.3M | ||
| Q1 24 | $29.1M | $52.6M |
| Q4 25 | — | $108.4M | ||
| Q3 25 | $73.9M | $-122.7M | ||
| Q2 25 | — | $-120.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | $179.2M | ||
| Q2 24 | — | $65.3M | ||
| Q1 24 | — | $51.9M |
| Q4 25 | — | 36.6% | ||
| Q3 25 | 26.5% | -44.3% | ||
| Q2 25 | — | -46.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | 110.5% | ||
| Q2 24 | — | 51.1% | ||
| Q1 24 | — | 40.6% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | -0.18× | 5.82× | ||
| Q3 25 | 1.03× | -3.86× | ||
| Q2 25 | 2.40× | -21.43× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
UPST
| Personal Lending Segment | $201.4M | 68% |
| Servicing Fees Net | $39.5M | 13% |
| Servicing Fees | $27.5M | 9% |
| Other | $15.7M | 5% |
| Borrower Fees | $8.4M | 3% |
| Collection Agency Fees | $3.5M | 1% |
